Maksim O. Shcheglov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maksim O. Shcheglov has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander V. Aksenov
Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., 355017 Stavropol, Russia
2 shared publications - Anna M. Zatsepilina
Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., 355017 Stavropol, Russia
2 shared publications - Daria I. Murashkina
Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., 355017 Stavropol, Russia
2 shared publications - Dmitrii A. Aksenov
North Caucasus Federal University, Stavropol, Russia
2 shared publications - Nicolai Alexandrovich Aksenov
Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., 355017 Stavropol, Russia
2 shared publications - Nikolai A. Arutiunov
Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., 355017 Stavropol, Russia
2 shared publications
Latest Publications
- Open Access
Synthesis and Evaluation of Cytotoxic Activity of 2-Aryl-2-(3-Indolyl)Propionic Acid Derivatives
2-Aryl-2-(3-indolyl)acetohydroxamic acids have emerged as promising antitumor agents; however, their poor pharmacokinetic profile remains a significant drawback. To address this limitation, we have synthesized a homolog of such acids—specifically 2-aryl-2-(3-indolyl)propionic acid (IC50 > 100 mM (U87)), along with several other derivatives: ethyl ester (IC50 > 100 mM (U87)), hydroxamate (IC50 21.2 ± 1.0 mM (U87)) and hydrazide (IC50 > 100 mM (U87)). The cytotoxicity of these compounds against glioblastoma cell lines was evaluated and compared to that of the parent acetohydroxamic acid derivatives.
Open AccessSynthesis and Evaluation of Cytotoxic Activity of 2-Aryl-2-(3-Indolyl)Propionic Acid Derivatives
2-Aryl-2-(3-indolyl)acetohydroxamic acids have emerged as promising antitumor agents; however, their poor pharmacokinetic profile remains a significant drawback. To address this limitation, we have synthesized a homolog of such acids—specifically 2-aryl-2-(3-indolyl)propionic acid (IC50 > 100 mM (U87)), along with several other derivatives: ethyl ester (IC50 > 100 mM (U87)), hydroxamate (IC50 21.2 ± 1.0 mM (U87)) and hydrazide (IC50 > 100 mM (U87)). The cytotoxicity of these compounds against glioblastoma cell lines was evaluated and compared to that of the parent acetohydroxamic acid derivatives.
- Open Access
- 24 December 2025
- Published by MDPI AG in Preprints.org
Synthesis and Evaluation of Cytotoxic Activity of 2-Aryl-2-(3-indolyl)propionic Acid Derivatives
2-Aryl-2-(3-indolyl)acetohydroxamic acids have emerged as promising antitumor agents; however, their poor pharmacokinetic profile remains a significant drawback. To address this limitation, we have synthesized homologs of such an acids—specifically 2-aryl-2-(3-indolyl)propionic acids—along with several other derivatives. The cytotoxicity of these compounds against glioblastoma cell lines was evaluated and compared to that of the parent acetohydroxamic acid derivatives.
- 24 December 2025
- Published by MDPI AG in Preprints.org
Open AccessSynthesis and Evaluation of Cytotoxic Activity of 2-Aryl-2-(3-indolyl)propionic Acid Derivatives
2-Aryl-2-(3-indolyl)acetohydroxamic acids have emerged as promising antitumor agents; however, their poor pharmacokinetic profile remains a significant drawback. To address this limitation, we have synthesized homologs of such an acids—specifically 2-aryl-2-(3-indolyl)propionic acids—along with several other derivatives. The cytotoxicity of these compounds against glioblastoma cell lines was evaluated and compared to that of the parent acetohydroxamic acid derivatives.